Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M

MADRIGAL PHARMACEUTICALS, INC.

Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.
Net loss $57.9M ($1.99/share) vs. $42.3M ($1.50/share) a year ago; includes $25M one-time business development expense.
Cash and marketable securities $838.9M as of June 30, 2026, down from $988.6M at Dec. 31, 2025.
Three new resmetirom patents issued, including one for F4c (well-compensated cirrhosis) with protection into 2042.
MGL-2086 (oral GLP-1) Phase 1 SAD trial initiated in June 2026 for Rezdiffra combination program in MASH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.